Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials

被引：0
|
作者：
Liedtke, W [1 ]
Limmroth, V [1 ]
机构：
[1] NIH,OFF DIRECTOR,LAB DIAGNOST RADIOL RES,BETHESDA,MD 20892
来源：
ANNALS OF NEUROLOGY | 1996年 / 39卷 / 02期
关键词：
D O I：
10.1002/ana.410390221
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：276 / 276
页数：1
相关论文
共 50 条
  • [1] MRI as an outcome in multiple sclerosis clinical trials
    Daumer, M.
    Neuhaus, A.
    Morrissey, S.
    Hintzen, R.
    Ebers, G. C.
    NEUROLOGY, 2009, 72 (08) : 705 - 711
  • [2] MRI AS AN OUTCOME IN MULTIPLE SCLEROSIS CLINICAL TRIALS Reply
    Ebers, George
    Daumer, Martin
    NEUROLOGY, 2009, 73 (22) : 1932 - 1933
  • [3] Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis
    Cawley, Niamh
    Tur, Carmen
    Prados, Ferran
    Plantone, Domenico
    Kearney, Hugh
    Abdel-Aziz, Khaled
    Ourselin, Sebastian
    Wheeler-Kingshott, Claudia A. M. Gandini
    Miller, David H.
    Thompson, Alan J.
    Ciccarelli, Olga
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (07) : 932 - 941
  • [4] MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No
    Ebers, George C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 282 - 283
  • [5] Statistical Efficiency of Phase II Multiple Sclerosis Clinical Trials with Different MRI Scanning Frequencies
    Zhao, Y.
    Chen, J.
    Li, D. K. B.
    Riddehough, A.
    Traboulsee, A.
    Petkau, A. J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 680 - 680
  • [6] Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
    Rossman, Ian T.
    Cohen, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) : 489 - 491
  • [7] Construct validity of potential multiple sclerosis clinical trial MRI outcome measures
    Cookfair, D. L.
    Benedict, R. H. B.
    Zivadinov, R.
    JOURNAL OF NEUROLOGY, 2006, 253 : 82 - 82
  • [8] MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
    Hutchinson, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 284 - 285
  • [9] MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes
    Sormani, Maria Pia
    De Stefano, Nicola
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 280 - 281
  • [10] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Bernard M. J. Uitdehaag
    CNS Drugs, 2018, 32 : 543 - 558
12345